ISUOG updated consensus statement on the impact of cfDNA aneuploidy testing on screening policies and prenatal ultrasound practice

Ultrasound Obstet Gynecol. 2017 Jun;49(6):815-816. doi: 10.1002/uog.17483.
No abstract available

MeSH terms

  • Aneuploidy*
  • Biomarkers / blood
  • Cell-Free Nucleic Acids / blood*
  • Consensus*
  • DNA / blood*
  • Down Syndrome / diagnosis
  • Down Syndrome / genetics*
  • Female
  • Humans
  • Maternal Serum Screening Tests
  • Predictive Value of Tests
  • Pregnancy
  • Pregnancy Trimester, First
  • Risk Assessment
  • Societies, Medical
  • Trisomy 13 Syndrome / diagnosis
  • Trisomy 13 Syndrome / genetics*
  • Trisomy 18 Syndrome / diagnosis
  • Trisomy 18 Syndrome / genetics*
  • Ultrasonography, Prenatal

Substances

  • Biomarkers
  • Cell-Free Nucleic Acids
  • DNA